RSS Feeds
Search

Companies

Pharmacyclics

Summary

Pharmacyclics was founded in 1991 based on the unique scientific collaboration between the company's co-founders, Jonathan L. Sessler, Ph.D. and Richard A. Miller, M.D. The founders met when Dr. Miller was treating Dr. Sessler for cancer, at Stanford University Medical Center in the early 1980s. Informal conversations between the two about how Sessler, a graduate student in chemistry at Stanford, might apply his knowledge to create novel treatments for cancer led to more focused laboratory experiments. Based on interactions between the two over the next several years, Sessler and his colleagues developed the "texaphyrin" molecules, so named because they were discovered at the University of Texas, where Sessler was now working. The Dr.'s Miller and Sessler formed Pharmacyclics, licensing the texaphyrin technology from the University of Texas. The company, which went public in October 1995, still owns the worldwide marketing rights to all of its proprietary products developed from the texaphyrin platform.

R&D

Pharmacyclics' technology platform is based on several novel classes of small-molecule pharmaceuticals. Each is rationally designed to target cancer and autoimmune diseases in unique ways.

The products under development at Pharmacyclics include:

Xcytrin® (motexafin gadolinium) Injection, Pharmacyclics' most advanced drug candidate, is under evaluation for use in patients with brain metastases from non-small cell lung cancer and other cancers.

Xcytrin is the first in a class of drugs called texaphyrins, which selectively target cancer, inhibiting metabolism and inducing cell death by apoptosis.

HDAC Inhibitors, which include PCI-24781, a compound now in clinical testing. These drugs are being developed as cancer therapies based on their ability to alter gene expression to bring about tumor cell death.

Factor VIIa Inhibitors, small-molecule inhibitors of Factor VIIa that are designed to treat cancer by inhibiting angiogenesis and tumor growth.

B-cell Tyrosine Kinase Inhibitors, potential treatments for autoimmune diseases and lymphomas based on their ability to stop the proliferation of immune cells known as B-cells.

Partnerships

Pharmacyclics has been engaged in collaborations with National Cancer Institute, Alcon and Nycomed and has made several agreements with The University of Texas.

Senior management

Richard A. Miller, M.D. (President, Chief Executive Officer and Director)
Dr. Miller co-founded in April 1991. In 1984, Dr. Miller co-founded IDEC Pharmaceuticals Corporation, a public biotechnology company, where he served as Vice President and a Director until February 1992. Dr. Miller also is a Clinical Professor of Medicine (Oncology) at Stanford University Medical Center. Dr. Miller received his M.D., summa cum laude, from the State University of New York Medical School and is board certified in both Internal Medicine and Medical Oncology.

Leiv Lea, M.B.A. (Vice President, Finance and Administration and Chief Financial Officer)
Mr. Lea served as a financial consultant for high technology companies and was Acting Chief Financial Officer for Global Village Communications, Inc., from September 1996 through November 1997. From 1987 through June 1996 he served as Vice President and Chief Financial Officer of Margaux, Inc., a public company that manufactured refrigeration equipment. Mr. Lea received a B.S. degree in Agricultural Economics from the University of California, Davis and an M.B.A. from the University of California, Los Angeles.

Michael Inouye, M.B.A. (Senior Vice President, Corporate and Commercial Development)
Mr. Inouye, M.B.A. joined Pharmacyclics in May 2007 as Senior Vice President, Corporate & Commercial Development. From March 2006 to February 2007 he was at Telik, Inc., a development stage biopharmaceutical company focused in oncology as their Senior VP, Commercial Operations. During August 1995 through October 2004, Mr. Inouye was at Gilead Sciences and was responsible for building their initial commercial organization in the US to launch their first products and subsequently expanded their international capabilities as Senior VP, Commercial Operations. From May 1994 to July 1995 he was Vice President of Sales and Marketing at InSite Vision, a development stage ophthalmic drug delivery company. Prior to that, Mr. Inouye spent over 13 years at Merck & Co., Inc in management positions of increasing responsibility in sales, marketing, and business development; and three years at American Home Products in sales. Mr. Inouye has a B.S. in Food Science from the University of California, Davis and an MBA from California Polytechnic University, Pomona.

Markus F. Renschler, M.D. (Senior Vice President, Clinical Development)
Dr. Renschler has served as Senior Vice President, Clinical Development since May 2006. Prior to that, Dr. Renschler served as Vice President, Oncology Clinical Development, from May 2001 until May 2006, as Senior Director of Clinical Development from May 1998 to May 2001 and as Director of Clinical Development from January 1996 to May 1998. Dr. Renschler is also an Adjunct Clinical Associate Professor of Medicine/Oncology at Stanford University School of Medicine. He is board certified in Medical Oncology. Dr. Renschler received his M.D. from Stanford University and a B.A. degree in Public and International Affairs from Princeton University.

Gregory Hemmi, Ph.D. (Vice President, Chemical Operations)
Dr. Hemmi served as Senior Director, Chemical Development from January 2001 to April 2006 and as Director, Chemical Development from December 1997 to December 2000. Other positions held at Pharmacyclics include Group Leader, Chemical Development from May 1995 to November 1997 and Scientist from June 1992 to April 1995. After graduating with a B.S. in Chemistry, Dr. Hemmi received a Ph.D. from the University of Texas at Austin under the direction of Professor Jonathan L. Sessler.

David Loury, Ph.D. (Vice President, Preclinical Sciences)
Dr. Loury joined Pharmacyclics as Vice President, Preclinical Sciences in May 2006 with 20 years of pharmaceutical industry experience. Most recently Dr. Loury served at Celera Genomics as Senior Director of Toxicology from April 2003 to April 2006. Prior to that, Dr Loury directed Drug Disposition, and Toxicology at Essential Therapeutics and IntraBiotics Pharmaceuticals from January 1996 to May 2001. Dr. Loury has held positions of increasing responsibility in Preclinical Safety at Syntex Corporation and Roche Pharmaceuticals. He is a Diplomate of the American Board of Toxicology. Dr. Loury received a B.S. degree in Environmental Toxicology and a Ph.D. in Pharmacology and Toxicology from the University of California, Davis.

Hugo Madden, Ph.D. (Vice President, Technology Development)
Dr. Madden has served as Vice President, Technology Development since May 2006. Prior to that, Dr. Madden served as Vice President, Chemical Operations from June 1998 to April 2006. From September 1995 to June 1998 he was at Catalytica Pharmaceuticals, initially as Plant Manager of their California manufacturing facility and later as Director of Process Development. From 1977 to 1995, Dr. Madden was with Syntex Corporation, holding various positions in chemical development and quality at Syntex's chemical manufacturing facilities in Ireland, Colorado and The Bahamas. He has served as a consultant on chemical manufacturing issues to a number of California pharmaceutical companies. Dr. Madden received a B.A. degree in Chemistry from the University of Oxford and a Ph.D. from the University of London.

See-Chun Phan, M.D. (Vice President, Clinical Research)
Dr. Phan has served as Vice President, Clinical Research since June 2003. Prior to that, Dr. Phan served as Associate Director, Clinical Development from July 1998 to June 2000 and as Director, Clinical Development from June 2000 to June 2003. Dr. Phan trained in Internal Medicine, Hematology and Medical Oncology at Stanford. He is board certified in Internal Medicine and Medical Oncology. Dr. Phan received his M.D. from Columbia University College of Physicians and Surgeons and his B.S. degree in Molecular Biophysics and Biochemistry from Yale University.

Board of directors

Richard A. Miller, M.D. (Director, President and Chief Executive Officer)
Dr. Miller co-founded in April 1991. In 1984, Dr. Miller co-founded IDEC Pharmaceuticals Corporation, a public biotechnology company, where he served as Vice President and a Director until February 1992. Dr. Miller also is a Clinical Professor of Medicine (Oncology) at Stanford University Medical Center. Dr. Miller received his M.D., summa cum laude, from the State University of New York Medical School and is board certified in both Internal Medicine and Medical Oncology.

Miles R. Gilburne, J.D. (Director)
Mr. Gilburne is currently a managing member of ZG Ventures, LLC, a private investment firm. He has been active for more than 20 years as a venture capitalist, corporate strategist and technology lawyer in the media, communications and technology industries. Mr. Gilburne served for 5 years as Senior Vice President of Corporate Development for America Online, stepping down from those duties in December 1999. Mr. Gilburne was elected to the Board of Directors of AOL in 1999 and to the Board of Directors of AOL Time Warner, Inc in 2001. He also serves on the Board of Directors of Acirca, Inc, and the Board of Trustees for The American Cancer Society Foundation, The National Archives Foundation and The Washington Shakespeare Theatre. In addition, Mr. Gilburne is a founding director and Vice Chairman of In2Books, a Washington, DC based reading and literacy program. Mr. Gilburne received an AB from Princeton University and a JD from Harvard Law School.

James L. Knighton, M.B.A. (Director)
Mr. Knighton was elected as a Director of the Company in August 2006. He served as president, chief operating officer and chief financial officer of Caliper Life Sciences, Inc. from 2002-2004 and as chief financial officer from 1999-2002. From 1998-1999 he served as chief financial officer of SUGEN, Inc. until its acquisition by Pharmacia. Mr. Knighton held various positions at Chiron Corporation from 1994-1998 including vice president of worldwide operations, vice president of business operations and vice president, investor relations and corporate communications. Previously he was vice president of strategic planning and finance at DuPont Merck. He received a M.S. in Genetics from University of Pennsylvania and a M.B.A. from the Wharton School. Mr. Knighton currently is the president and co-founder of AvidBiotics Corporation, a private biotechnology company

Richard M. Levy, Ph.D (Director)
Dr. Levy currently serves as president and chief executive officer of Varian Medical Systems, Inc., a world leading manufacturer of integrated cancer therapy systems and supplier of X-ray tubes and flat-panel digital subsystems for imaging in medical, scientific, and industrial applications. Dr. Levy joined Varian as a regional sales manager in 1968. Prior to assuming general management and CEO duties at the company, he oversaw sales, marketing, service, R&D and various other corporate functions. Dr. Levy began his business career at the Monsanto Company, where he served as a research specialist and project manager in both basic and applied research. Dr. Levy holds a bachelor's degree from Dartmouth College and a doctorate in nuclear chemistry from the University of California at Berkeley.

William R. Rohn (Director)
Mr. Rohn currently serves as President and Chief Operating Officer at IDEC Pharmaceuticals in San Diego. Before joining IDEC in 1993, he spent nearly a decade at Adria Laboratories (now part of Pharmacia & Upjohn), serving in a variety of marketing and sales management positions, including senior vice president of commercial operations. Previous to joining Adria, he served for nearly ten years in several marketing and sales management positions at Abbott Laboratories. He earned his undergraduate degree in marketing from Michigan State University. Mr. Rohn currently serves on the Board of Directors of Cerus Corporation.

Christine A. White, M.D. (Director)
Dr. White, M.D. was elected as a Director of the Company in August 2006. She was previously with Biogen Idec from 1996 through 2005, where she most recently served as senior vice president, global medical affairs. At Biogen Idec, Dr. White played a key role in the clinical development, regulatory affairs and commercialization of both Rituxan® and Zevalin®. Prior to joining Biogen Idec, Dr. White served as director of clinical oncology research from 1994 to 1996 at the Sidney Kimmel Cancer Center in San Diego, California, and from 1984-1994 was on staff at Scripps Memorial Hospitals, San Diego where she was medical director of oncology research (1990-1994) and Chair of the Department of Medicine (1994). Dr. White received her medical degree from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology. Dr. White currently serves on several editorial boards, including Cancer Biotherapy and Radiopharmaceutical, Expert Review of Anti-cancer Therapy and Journal of Immunotherapy.

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2014 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us